- Previous Close
2,749.85 - Open
2,745.05 - Bid --
- Ask --
- Day's Range
2,573.00 - 2,769.60 - 52 Week Range
1,292.00 - 2,974.95 - Volume
18,075 - Avg. Volume
48,681 - Market Cap (intraday)
42.912B - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
46.48 - EPS (TTM)
55.82 - Earnings Date Oct 22, 2024 - Oct 26, 2024
- Forward Dividend & Yield 16.00 (0.58%)
- Ex-Dividend Date Jun 28, 2024
- 1y Target Est
--
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, and anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology, cardiovascular, pediatrics, neurology, anti-dengue, and dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
www.rpglifesciences.com1,270
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: RPGLIFE.NS
View MorePerformance Overview: RPGLIFE.NS
Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPGLIFE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPGLIFE.NS
View MoreValuation Measures
Market Cap
45.48B
Enterprise Value
44.22B
Trailing P/E
49.25
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.64
Price/Book (mrq)
12.13
Enterprise Value/Revenue
7.43
Enterprise Value/EBITDA
30.98
Financial Highlights
Profitability and Income Statement
Profit Margin
15.40%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
6B
Net Income Avi to Common (ttm)
923.2M
Diluted EPS (ttm)
55.82
Balance Sheet and Cash Flow
Total Cash (mrq)
1.26B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--